| Revenue growth | Broadly in line with FY25 at ₹3,744M. |
|---|---|
| Margins | EBITDA margins impacted by regulatory investments; projecting upper-teen margins post-remediation. |
| Demand visibility | Strong for NIP/OTF; $400M market opportunity for Dabigatran in Europe. |
| Management confidence | High; confident in EU GMP reinstatement following May 2026 inspection. |
Growth
FY26 revenue ₹3,744M; EBITDA ₹414M; PAT ₹58M. Q4 FY26 revenue ₹1,053M with 12.7% EBITDA margin.
Outlook
Guidance for mid-teen margins in FY27; expected commercialization of 17 NIP/OTF products within 24 months.
Risks
Geopolitical disruption in MENA caused ₹20-25cr impact; EU GMP compliance remains a critical dependency for regulated markets.
Earnings Call filed with NSE, NSE: ZIMLAB. Summary written with AI assistance from the document.
Zim Laboratories Ltd: key numbers
- Share price
- ₹138.48
- Market cap
- ₹743.1 Cr
- Revenue (annual)
- ₹374.4 Cr
- Net profit (annual)
- ₹5.84 Cr
- P/E (TTM)
- 201.0×Sector 50.4×
- Promoter holding
- 30.36%+0.01% QoQ
- FII holding
- 0.03%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Zim Laboratories Ltd
All →Zim Laboratories Merger & Restructuring Worth ₹1,404,640 Cr
ZIM Laboratories completed incorporation of its wholly-owned Chilean subsidiary, ZIM Laboratories SpA. The LATAM expansion entity is now operational, marking completion of the February 2026 board-approved plan.
- Value
- ₹14,04,640 Cr
Zim Laboratories Merger & Restructuring
ZIM Laboratories Limited incorporated a wholly owned subsidiary, 'ZIM Laboratories SpA', in Chile. This expansion aims to develop its pharmaceutical business in the LATAM region.
Zim Laboratories Acquisition Worth ₹1.56 Cr
ZIM WOS completed a ₹1.56 Crore investment in stepdown ZIM Scientific Office L.L.C., Dubai, fulfilling the board-approved capital plan. The transaction closes the acquisition announced in August 2025.
- Value
- ₹1.56 Cr
Zim Laboratories Merger & Restructuring Worth ₹2.38 Cr
Zim Laboratories confirmed that its subsidiary, ZIM FZE, completed the previously announced AED 9,16,000 investment in its step-down subsidiary, ZIM Scientific Office LLC.
- Value
- ₹2.38 Cr
Zim Laboratories Investor Presentation: Key Takeaways
Zim Laboratories reported 31.2% YoY revenue growth in Q1 FY27, driven by core pharma and exports (84% of income). Strategy focuses on EU-GMP remediation and expanding the innovation-led NIP/OTF portfolio.
- Call
- Guides 32% growth
Zim Laboratories Investor Presentation: Key Takeaways
Q1 FY27 Total Operating Income rose 31.2% YoY to ₹942 Mn. However, EBITDA fell 40% to ₹34 Mn due to utility/employee costs.